Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de John Renger
Age : 52
Public asset : 64,192 USD
Country of residence : Unknown
Linked companies : Cerevel Therapeutics Holdings, Inc.

Biography of John Renger 
Presently, John Renger is Chief Scientific Officer of Cerevel Therapeutics Holdings, Inc. In the past Dr. Renger was Associate Vice President at Merck & Co., Inc. and Vice President-Research & Development at Imbrium Therapeutics LP. He received a doctorate and an undergraduate degree from the University of Iowa.


Current positions of John Renger 
Holdings of John Renger 
John Renger : Personal Network 
Most Read News 
01/18ELON MUSK : Tesla investors urge judge to order Musk repay $13 billion for SolarCity deal
RE
01/11JAMIE DIMON : JPMorgan's Dimon says consumer loan growth may take 6-9 months to return to normal
RE
01/13JACK DORSEY : Jack Dorsey's Block to build an open bitcoin mining system
RE
01/14ELON MUSK : Musk says Tesla to accept dogecoin for merchandise
RE
01/20ALAN JOPE : Unilever strategy under scrutiny after short-lived GSK skirmish
RE
01/10BRUNELLO CUCINELLI : Luxury group Cucinelli posts 31% sales jump in 2021
RE
01/11CATHIE WOOD : ARK's Wood turns focus to deflation, 'stay connected' stocks
RE
01/12MARTIN SORRELL : Sorrell's S4 says trading well ahead of guidance
RE
01/13AMANCIO ORTEGA : Inditex founder Amancio Ortega buys Toronto's Royal Bank Plaza for $916 mln
RE
01/07RICHARD BRANSON : British tycoon Branson to list blank-check firm in Amsterdam, Sky News says
RE
More news


© 2022 People and Ownership :   
John Renger : Connections 


Latest news about John Renger 
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2020Cerevel Therapeutics, LLC completed the acquisition of ARYA Sciences Acquisition Corp II from Bain Capital, LP and others in a reverse merger transaction.
CI
2020Cerevel Therapeutics, LLC entered into a definitive business combination agreement to acquire ARYA Sciences Acquisition Corp II from Bain Capital, LP and others for $780 million in a reverse merger transaction.
CI
2020Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder
CI
More news